# Study of ALXN1820 in Healthy Adult Participants

> **NCT04631562** · PHASE1 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 66 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ALXN1820 SC
- **DRUG:** ALXN1820 IV
- **DRUG:** Placebo SC
- **DRUG:** Placebo IV

## Key facts

- **NCT ID:** NCT04631562
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-13
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04631562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04631562, "Study of ALXN1820 in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04631562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*